請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52805
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳青周 | |
dc.contributor.author | Chan-Lin Ku | en |
dc.contributor.author | 古展霖 | zh_TW |
dc.date.accessioned | 2021-06-15T16:28:28Z | - |
dc.date.available | 2020-09-24 | |
dc.date.copyright | 2015-09-24 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-13 | |
dc.identifier.citation | 1. Tenesa A Dunlop MG (2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. Nature reviews. Genetics 10(6):353-358. 2. Haggar FA Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clinics in colon and rectal surgery 22(4):191-197. 3. Ponz de Leon M Di Gregorio C (2001) Pathology of colorectal cancer. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 33(4):372-388. 4. Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138(6):2101-2114 e2105. 5. Ballinger AB Anggiansah C (2007) Colorectal cancer. BMJ 335(7622):715-718. 6. Magalhaes B, Peleteiro B, Lunet N (2012) Dietary patterns and colorectal cancer: systematic review and meta-analysis. Eur J Cancer Prev 21(1):15-23. 7. Markowitz SD Bertagnolli MM (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. The New England journal of medicine 361(25):2449-2460. 8. Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386(6625):623-627. 9. Papadopoulos N, et al. (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263(5153):1625-1629. 10. Herman JG, et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences of the United States of America 95(12):6870-6875. 11. Issa JP (2004) CpG island methylator phenotype in cancer. Nature reviews. Cancer 4(12):988-993. 12. Kondo Y Issa JP (2004) Epigenetic changes in colorectal cancer. Cancer metastasis reviews 23(1-2):29-39. 13. Toyota M, et al. (1999) CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 96(15):8681-8686. 14. Nosho K, et al. (2008) Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PloS one 3(11):e3698. 15. Goss KH Groden J (2000) Biology of the adenomatous polyposis coli tumor suppressor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 18(9):1967-1979. 16. Fearon ER BG (2008) Molecular biology of colorectal cancer. DeVita, Hellman, and Rosenberg’s cancer: principles practice of oncology. Vol. 1.:1218-1231. 17. Kinzler KW VBCtIVB, Kinzler KW, eds (2002) The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill:583-612. 18. Grady WM MS (2002) Colorectal cancer: genetic alterations. Gastrointestinal oncology: principles and practice.:685-702. 19. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249(4971):912-915. 20. Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nature reviews. Drug discovery 7(12):979-987. 21. Bos JL, et al. (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327(6120):293-297. 22. Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954. 23. Rajagopalan H, et al. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418(6901):934. 24. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. Journal of the National Cancer Institute 101(19):1308-1324. 25. Samuels Y, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554. 26. Parsons DW, et al. (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436(7052):792. 27. Cha YI DuBois RN (2007) NSAIDs and cancer prevention: targets downstream of COX-2. Annual review of medicine 58:239-252. 28. Saltz LB, et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22(7):1201-1208. 29. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England journal of medicine 350(23):2335-2342. 30. Lynch HT de la Chapelle A (1999) Genetic susceptibility to non-polyposis colorectal cancer. Journal of medical genetics 36(11):801-818. 31. Peltomaki P, et al. (1993) Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer research 53(24):5853-5855. 32. Boland CR, et al. (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer research 58(22):5248-5257. 33. Lieberman DA (2009) Clinical practice. Screening for colorectal cancer. The New England journal of medicine 361(12):1179-1187. 34. Mandel JS, et al. (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. The New England journal of medicine 343(22):1603-1607. 35. Levin B, et al. (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA: a cancer journal for clinicians 58(3):130-160. 36. Lieberman D, Moravec M, Holub J, Michaels L, Eisen G (2008) Polyp size and advanced histology in patients undergoing colonoscopy screening: implications for CT colonography. Gastroenterology 135(4):1100-1105. 37. Brenner DJ Hall EJ (2007) Computed tomography--an increasing source of radiation exposure. The New England journal of medicine 357(22):2277-2284. 38. Selby JV, Friedman GD, Quesenberry CP, Jr., Weiss NS (1992) A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. The New England journal of medicine 326(10):653-657. 39. Lieberman DA, et al. (2000) Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. The New England journal of medicine 343(3):162-168. 40. Regula J, et al. (2006) Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. The New England journal of medicine 355(18):1863-1872. 41. Muller AD Sonnenberg A (1995) Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Annals of internal medicine 123(12):904-910. 42. Singh H, Turner D, Xue L, Targownik LE, Bernstein CN (2006) Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. Jama 295(20):2366-2373. 43. Baxter NN, et al. (2009) Association of colonoscopy and death from colorectal cancer. Annals of internal medicine 150(1):1-8. 44. Greene FL BC, Fleming ID, et al.,eds. (2009) AJCC cancer staging handbook. 7th ed. New York: Springer. 45. Cunningham D, et al. (2010) Colorectal cancer. Lancet 375(9719):1030-1047. 46. Camma C, et al. (2000) Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. Jama 284(8):1008-1015. 47. Chakravarti A, et al. (1999) Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. Annals of surgery 230(1):49-54. 48. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews. Drug discovery 3(5):391-400. 49. McCormack PL Keam SJ (2008) Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs 68(4):487-506. 50. Graham J, Muhsin M, Kirkpatrick P (2004) Cetuximab. Nature reviews. Drug discovery 3(7):549-550. 51. Keating GM (2010) Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 70(8):1059-1078. 52. Goodwin RA Asmis TR (2009) Overview of systemic therapy for colorectal cancer. Clinics in colon and rectal surgery 22(4):251-256. 53. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389(6648):251-260. 54. Wasylyk B Chambon P (1979) Transcription by eukaryotic RNA polymerases A and B of chromatin assembled in vitro. European journal of biochemistry / FEBS 98(2):317-327. 55. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature reviews. Drug discovery 1(4):287-299. 56. Jenuwein T Allis CD (2001) Translating the histone code. Science 293(5532):1074-1080. 57. Lee KK Workman JL (2007) Histone acetyltransferase complexes: one size doesn't fit all. Nature reviews. Molecular cell biology 8(4):284-295. 58. Shahbazian MD Grunstein M (2007) Functions of site-specific histone acetylation and deacetylation. Annual review of biochemistry 76:75-100. 59. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature reviews. Genetics 10(1):32-42. 60. Marks PA (2010) Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochimica et biophysica acta 1799(10-12):717-725. 61. Brunmeir R, Lagger S, Seiser C (2009) Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation. The International journal of developmental biology 53(2-3):275-289. 62. Taplick J, et al. (2001) Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. Journal of molecular biology 308(1):27-38. 63. Yang XJ Seto E (2008) The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nature reviews. Molecular cell biology 9(3):206-218. 64. Hayakawa T Nakayama J (2011) Physiological roles of class I HDAC complex and histone demethylase. Journal of biomedicine biotechnology 2011:129383. 65. Parra M Verdin E (2010) Regulatory signal transduction pathways for class IIa histone deacetylases. Current opinion in pharmacology 10(4):454-460. 66. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F (2008) HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends in cell biology 18(6):291-297. 67. Li G, Jiang H, Chang M, Xie H, Hu L (2011) HDAC6 alpha-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases. Journal of the neurological sciences 304(1-2):1-8. 68. Aldana-Masangkay GI Sakamoto KM (2011) The role of HDAC6 in cancer. Journal of biomedicine biotechnology 2011:875824. 69. Schwer B Verdin E (2008) Conserved metabolic regulatory functions of sirtuins. Cell metabolism 7(2):104-112. 70. Gao L, Cueto MA, Asselbergs F, Atadja P (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. The Journal of biological chemistry 277(28):25748-25755. 71. Liu H, Hu Q, Kaufman A, D'Ercole AJ, Ye P (2008) Developmental expression of histone deacetylase 11 in the murine brain. Journal of neuroscience research 86(3):537-543. 72. Juan LJ, et al. (2000) Histone deacetylases specifically down-regulate p53-dependent gene activation. The Journal of biological chemistry 275(27):20436-20443. 73. West AC Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. The Journal of clinical investigation 124(1):30-39. 74. Kramer OH, et al. (2009) A phosphorylation-acetylation switch regulates STAT1 signaling. Genes development 23(2):223-235. 75. Place RF, Noonan EJ, Giardina C (2005) HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochemical pharmacology 70(3):394-406. 76. Minucci S Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature reviews. Cancer 6(1):38-51. 77. New M, Olzscha H, La Thangue NB (2012) HDAC inhibitor-based therapies: can we interpret the code? Molecular oncology 6(6):637-656. 78. Glozak MA Seto E (2007) Histone deacetylases and cancer. Oncogene 26(37):5420-5432. 79. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C (2009) Histone deacetylase inhibitors and genomic instability. Cancer letters 274(2):169-176. 80. Luo J, Su F, Chen D, Shiloh A, Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408(6810):377-381. 81. Duan H, Heckman CA, Boxer LM (2005) Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Molecular and cellular biology 25(5):1608-1619. 82. Gelmetti V, et al. (1998) Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Molecular and cellular biology 18(12):7185-7191. 83. Deroanne CF, et al. (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21(3):427-436. 84. Vannini A, et al. (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proceedings of the National Academy of Sciences of the United States of America 101(42):15064-15069. 85. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proceedings of the National Academy of Sciences of the United States of America 97(18):10014-10019. 86. Marks P, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nature reviews. Cancer 1(3):194-202. 87. Huang L Pardee AB (2000) Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6(10):849-866. 88. Kim MS, et al. (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer research 63(21):7291-7300. 89. Fuino L, et al. (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Molecular cancer therapeutics 2(10):971-984. 90. Nimmanapalli R, et al. (2003) Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer research 63(16):5126-5135. 91. Hideshima T, et al. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 102(24):8567-8572. 92. Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research 10(11):3839-3852. 93. Duvic M, et al. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31-39. 94. Nebbioso A, Carafa V, Benedetti R, Altucci L (2012) Trials with 'epigenetic' drugs: an update. Molecular oncology 6(6):657-682. 95. Qiu T, et al. (2013) Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol 9(2):255-269. 96. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nature reviews. Drug discovery 5(9):769-784. 97. Simons K Vaz WL (2004) Model systems, lipid rafts, and cell membranes. Annual review of biophysics and biomolecular structure 33:269-295. 98. Goldstein JL Brown MS (1990) Regulation of the mevalonate pathway. Nature 343(6257):425-430. 99. Petras SF, Lindsey S, Harwood HJ, Jr. (1999) HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells. Journal of lipid research 40(1):24-38. 100. Istvan ES (2001) Bacterial and mammalian HMG-CoA reductases: related enzymes with distinct architectures. Current opinion in structural biology 11(6):746-751. 101. Hampton R, Dimster-Denk D, Rine J (1996) The biology of HMG-CoA reductase: the pros of contra-regulation. Trends in biochemical sciences 21(4):140-145. 102. Hardie DG Carling D (1997) The AMP-activated protein kinase--fuel gauge of the mammalian cell? European journal of biochemistry / FEBS 246(2):259-273. 103. Bengtsson E, et al. (2014) HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome. Diagnostic pathology 9:78. 104. Clendening JW, et al. (2010) Dysregulation of the mevalonate pathway promotes transformation. Proceedings of the National Academy of Sciences of the United States of America 107(34):15051-15056. 105. Zhong C, et al. (2014) HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 35(5):4123-4129. 106. Istvan ES Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292(5519):1160-1164. 107. Ness GC, Zhao Z, Lopez D (1996) Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Archives of biochemistry and biophysics 325(2):242-248. 108. Sacks FM, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. The New England journal of medicine 335(14):1001-1009. 109. Thurnher M, Nussbaumer O, Gruenbacher G (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clinical cancer research : an official journal of the American Association for Cancer Research 18(13):3524-3531. 110. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nature reviews. Cancer 5(12):930-942. 111. Hindler K, Cleeland CS, Rivera E, Collard CD (2006) The role of statins in cancer therapy. The oncologist 11(3):306-315. 112. Swanson KM Hohl RJ (2006) Anti-cancer therapy: targeting the mevalonate pathway. Current cancer drug targets 6(1):15-37. 113. Rao S, et al. (1999) Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proceedings of the National Academy of Sciences of the United States of America 96(14):7797-7802. 114. Ukomadu C Dutta A (2003) p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. The Journal of biological chemistry 278(44):43586-43594. 115. Veillard NR Mach F (2002) Statins: the new aspirin? Cellular and molecular life sciences : CMLS 59(11):1771-1786. 116. Youssef S, et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420(6911):78-84. 117. Denoyelle C, et al. (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22(8):1139-1148. 118. Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59(11):1572-1585. 119. Lin YC, et al. (2008) Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer research 68(7):2375-2383. 120. Gan Y, Wang J, Coselli J, Wang XL (2008) Synergistic induction of apoptosis by HMG-CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cells. Biochemical and biophysical research communications 365(2):386-392. 121. Falkenberg KJ Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nature reviews. Drug discovery 13(9):673-691. 122. Jawaid S, et al. (2010) Human hydroxymethylglutaryl-coenzyme A reductase (HMGCR) and statin sensitivity. Indian journal of biochemistry biophysics 47(6):331-339. 123. Chen JB, et al. (2013) Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. Journal of medicinal chemistry 56(9):3645-3655. 124. Lin KT, et al. (2012) HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 18(17):4691-4701. 125. Xia D, Wang D, Kim SH, Katoh H, DuBois RN (2012) Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nature medicine 18(2):224-226. 126. Meyerhardt JA Mayer RJ (2005) Systemic therapy for colorectal cancer. The New England journal of medicine 352(5):476-487. 127. Chibaudel B, Tournigand C, Andre T, de Gramont A (2012) Therapeutic strategy in unresectable metastatic colorectal cancer. Therapeutic advances in medical oncology 4(2):75-89. 128. Braun RD, Lanzen JL, Snyder SA, Dewhirst MW (2001) Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. American journal of physiology. Heart and circulatory physiology 280(6):H2533-2544. 129. Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH (2009) Exploitation of protein kinase C: a useful target for cancer therapy. Cancer treatment reviews 35(1):1-8. 130. Greenhough A, et al. (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30(3):377-386. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52805 | - |
dc.description.abstract | 大腸直腸癌為全球發生率第三之癌症,遠端轉移為致死主因,轉移性大腸直腸癌為無法治癒之疾病,標靶藥物合併化學治療可延長病患存活時間,為目前轉移性大腸直腸癌之治療準則,因此,研發新藥以延長病患存活時間為目前研究之重要方向。我們研發JMF compound為抑制HMGCR和HDAC活性之小分子藥物,實驗發現hydroxymate group binding HDAC之抑制效果最佳,JMF3086與金屬離子結合於缺氧環境可釋放JMF3086單體,抑制xenograft動物模式腫瘤;抑制大腸直腸癌之肝臟轉移中,JMF3086與化療藥物irinotecan合併使用具加成性,顯示JMF3086為極具潛力之抗癌藥物。HMGCR於癌症中有過度表現之現象,但其扮演角色仍不清楚,我們發現HMGCR之過度表現可促進腫瘤細胞之存活,並增加COX-2和DNMT蛋白之表現;反之,抑制HMGCR則促進細胞凋亡,顯示HMGCR於腫瘤細胞中扮演促進腫瘤生長之角色,是癌症治療之標的。 | zh_TW |
dc.description.abstract | Colorectal cancer (CRC) is the third most common cancer in the world and metastases are the main cause of death in CRC. Metastatic CRC is incurable, discovery of new chemotherapeutic and molecular target angents prolongs the survival of metastatic CRC, implying the necessity of new drug development. We designed the dual-function anticancer agent to target both 3-hydroxy-3methylgutaryl CoA reductase (HMGCR) and histone deacetylase (HDAC). In this study, the hydroxymate-containing HDACi (JMF3086) exhibits most potency to inhibit the HDAC activity. JMF3086 metallo-complexes could release JMF3086, so that to inhibit tumor growth in CRC xenograft models. In spleen-liver metastasis model, JMF3086 showed synergistic effect with irinotecan in vivo, indicating JMF3086 as a potential anticancer agent. HMGCR is overexpressed in cancers, but how HMGCR interconnects with oncogenic signaling are still unclear. We found that overexpression of HMGCR could promote cell growth and induce the expressions of COX-2 and DNMT in CRC cells. On the contrary, knockdown of HMGCR could promote apoptosis. These results indicated HMGCR plays an important role in tumor growth, and HMGCR can be a therapeutic target for cancer treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T16:28:28Z (GMT). No. of bitstreams: 1 ntu-104-R02443004-1.pdf: 6397192 bytes, checksum: 91c2e45a614afe6e9e7e08bfecb5f091 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 縮寫表…………………………………………………………………………………2
中文摘要………………………………………………………………………………5 英文摘要………………………………………………………………………………6 第一章 緒論…………………………………………………………………………..7 第一節 大腸直腸癌 (Colorectal cancer) …………………………………………8 第二節 HDAC inhibitor…………………………………………………………..18 第三節 Statin……………………………………………………………………...31 第四節 研究動機…………………………………………………………………40 第二章 實驗材料與方法……………………………………………………………41 第三章 結果………………………………………………………………………....47 第四章 討論…………………………………………………………………………59 第五章 結論…………………………………………………………………………63 補充資料……………………………………………………………………………..65 參考文獻……………………………………………………………………………..67 | |
dc.language.iso | zh-TW | |
dc.title | HDAC和HMGCR抑制劑在大腸直腸癌之研究 | zh_TW |
dc.title | Investigation of dual inhibitors targeting HDAC and HMGCR in colorectal cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳明賢,黃偉謙 | |
dc.subject.keyword | 大腸直腸癌,新藥,轉移, | zh_TW |
dc.subject.keyword | colorectal cancer,new drug,metastasis, | en |
dc.relation.page | 79 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 6.25 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。